Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
111In-DTPA-NLS-chIgG1
- Development stage
- Discontinued
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
111In-DTPA-NLS-chIgG1 is a non-specific radioimmunoconjugate (RIC) primarily used as an isotype-matched negative control in preclinical research, particularly in the field of Auger electron radioimmunotherapy for acute myeloid leukemia (AML). It consists of a chimeric IgG1 monoclonal antibody (chIgG1) conjugated with diethylenetriaminepentaacetic acid (DTPA) as a chelator and nuclear localization sequence (NLS) peptides, radiolabeled with the Auger electron emitter Indium-111 (111In). Unlike targeted agents such as 111In-DTPA-NLS-CSL360, this construct lacks specific binding to therapeutic targets like CD123 or CD131. It is used to differentiate between target-specific cytotoxicity and non-specific radiation effects in cellular and animal models.
- Other names
- 111In-DTPA-chIgG1indium-111-DTPA-NLS-chIgG1indium111-DTPA-NLS-chIgG1indium 111-DTPA-NLS-chIgG1
Beyond the preview
Go deeper on 111In-DTPA-NLS-chIgG1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 111In-DTPA-NLS-chIgG1.